Table 1.

Mean number of trials ± SEM for the three measures in Experiments 1–4 under the different testing and drug conditions

Acquisition criterionTrials to criterionNo. of probe trials
Experiment 1
 Place version
   Vehicle–vehicle57.6  ± 12.763.1  ± 12.92.0  ± 0.7
   Vehicle–tetracaine50.3  ± 6.655.8  ± 7.41.8  ± 0.5
   Tetracaine–vehicle38.7  ± 4.360.3  ± 7.0*4.8  ± 1.4**
 Response version
  Vehicle– vehicle64.7  ± 11.064.7  ± 11.01.0  ± 0.0
   Vehicletetracaine108.3  ± 6.2**110.8  ± 5.1**1.3  ± 0.3
   Tetracainevehicle68.5  ± 11.668.5  ± 11.61.0  ± 0.0
Experiment 2
 Response version
   Vehicle–vehicle57.5  ± 13.670.3  ± 10.32.3  ± 0.6
   Vehicle–tetracaine68.2  ± 10.673.0  ± 10.61.8  ± 0.5
   Tetracaine–vehicle51.0  ± 14.751.0  ± 14.71.0  ± 0.0
 Place version
  Vehicle– vehicle36.2  ± 4.237.8  ± 4.71.2  ± 0.2
  Vehicle– tetracaine62.7  ± 7.8**67.3  ± 9.7**1.8  ± 0.5
  Tetracaine– vehicle40.0  ± 5.544.2  ± 3.91.7  ± 0.3
Experiment 3
 Place acquisition
   Vehicle–vehicle56.4  ± 12.868.0  ± 10.52.2  ± 0.7
   Vehicle–tetracaine61.2  ± 12.064.2  ± 12.41.6  ± 0.2
 Place reversal
  Vehicle– vehicle52.6  ± 6.455.6  ± 5.61.6  ± 0.6
  Vehicle– tetracaine59.4  ± 3.869.8  ± 8.02.2  ± 0.6
Experiment 4
 Response acquisition
   Vehicle–vehicle68.2  ± 13.472.6  ± 14.41.6  ± 0.2
   Vehicle–tetracaine70.0  ± 18.579.2  ± 17.81.8  ± 0.4
 Response reversal
  Vehicle– vehicle71.6  ± 15.875.6  ± 14.91.4  ± 0.4
  Vehicle– tetracaine72.0  ± 15.773.4  ± 16.01.2  ± 0.3
  • Underlined is the treatment administered for that condition.

  • *p < 0.05 versus acquisition criterion.

  • **p < 0.05 versus vehicle-injected controls.